Abstract:
A method and apparatus are directed to providing a dopant profile adjustment solution in plasma doping systems for meeting both concentration and junction depth requirements. Bias ramping and bias ramp rate adjusting may be performed to achieve a desired dopant profile so that shallow and abrupt junctions in vertical and lateral directions are realized that are critical to device scaling in plasma doping systems.
Abstract:
Pharmaceutical, cosmetic and pesticidal compositions containing a trifluoroacetyl-resorcinol of the formula ##STR1## wherein R.sub.2 and R.sub.4, which may be identical to or different from each other, are each hydrogen or methyl, andR.sub.3 and R.sub.5, which may be identical to or different from each other, are each hydrogen or ethyl.
Abstract:
A method to provide a dopant profile adjustment solution in plasma doping systems for meeting both concentration and junction depth requirements. Bias ramping and bias ramp rate adjusting may be performed to achieve a desired dopant profile so that surface peak dopant profiles and retrograde dopant profiles are realized. The method may include an amorphization step in one embodiment.
Abstract:
A method and apparatus are directed to providing a dopant profile adjustment solution in plasma doping systems for meeting both concentration and junction depth requirements. Bias ramping and bias ramp rate adjusting may be performed to achieve a desired dopant profile so that shallow and abrupt junctions in vertical and lateral directions are realized that are critical to device scaling in plasma doping systems.
Abstract:
A jewelry clasp has a first and a second clasp member connected to one another for closing the clasp. At least the first clasp member has a spring-weighed element for achieving a fixation of a closed position of the clasp. The first clasp member has a first end portion with a first end face and further has a first receiving opening extending transverse to the longitudinal extension of the first clasp member. The second clasp member has a second end portion with a second end face and further has a second receiving opening extending transverse to a longitudinal extension of the second clasp member. The first receiving opening is oriented oppositely to the second receiving opening. The first and the second end portions are insertable into one another such that in a closed position of the clasp the spring-weighed element is forced against the second end face of the second clasp member.
Abstract:
A method to provide a dopant profile adjustment solution in plasma doping systems for meeting both concentration and junction depth requirements. Bias ramping and bias ramp rate adjusting may be performed to achieve a desired dopant profile so that surface peak dopant profiles and retrograde dopant profiles are realized. The method may include an amorphization step in one embodiment.
Abstract:
Compounds of the formula ##STR1## wherein R.sub.1 is perfluoroalkyl of 1 to 8 carbon atoms or 2,2,3,3-tetrafluoro-cyclobutyl,R.sub.2 and R.sub.4, which may be identical to or different from each other, are each hydrogen, alkyl of 1 to 10 carbon atoms, aliphatic acyl of 2 to 18 carbon atoms, benzoyl, salicyloyl or phenylacetyl, andR.sub.3 and R.sub.5, which may be identical to or different from each other, are each alkyl of 3 to 18 carbon atoms, halogen, nitro, p-toluenesulfonyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclododecyl, methylcyclohexyl, dimethylcyclohexyl, benzyl, methylthio or ##STR2## where R.sub.1, R.sub.2 and R.sub.4 have the meanings previously defined,Q is --CH.sub.2 -- or --S--, andG is R.sub.5, as above defined, orQ is R.sub.3, as above defined, andG is --CH.sub.2 -- or --S--,R.sub.3 may, in addition, also be hydroxyl, methoxy, methyl or cyano, andR.sub.5 may also be methyl, orone of substituents R.sub.3 and R.sub.5 is hydrogen or ethyl when the other has the meanings defined above except hydrogen, or when R.sub.1 has the meanings defined above except trifluoromethyl, or when R.sub.2 and R.sub.4 have the meanings defined above except hydrogen or methyl. The compounds are useful as active ingredients in pharmaceutical, cosmetic and pesticidal compositions.
Abstract:
Small, polybasic peptides are disclosed that are effective as furin inhibitors, e.g. hexa- to nona-peptides having L-Arg or L-Lys in most positions. Removing the peptide terminating groups can improve inhibition of furin. High inhibition was seen in a series of non-amidated and non-acetylated polyarginines. The most potent inhibitor identified to date, nona-L-arginine, had a Ki against furin of 40 nM. Non-acetylated, poly-D-arginine-derived molecules are preferred furin inhibitors for therapeutic uses, such as inhibiting certain bacterial infections, viral infections, and cancers. Due to their relatively small size, these peptides should be non-immunogenic. These peptides are efficiently transported across cell membranes.